Table 4.
Estimated Prevalence of Chronic Kidney Disease and GFR Stages among U.S. Adults.*
| Equation† | Black Persons | Non-Black Persons | ||||
|---|---|---|---|---|---|---|
| No. in Millions | Weighted Percent | Change from eGFRcr(ASR)‡ | No. in Millions | Weighted Percent | Change from eGFRcr(ASR)‡ | |
| percent | percent | |||||
| Chronic kidney disease § | ||||||
| Creatinine | ||||||
| eGFRcr(ASR), current | 4.56±0.36 | 14.34±1.13 | Reference | 25.17±2.00 | 11.72±0.93 | Reference |
| eGFRcr(ASR-NB), new | 5.65±0.40 | 17.77±1.26 | 3.4±0.42 | 25.17±1.99 | 11.72±0.93 | 0 |
| eGFRcr(AS), new | 5.18±0.38 | 16.32±1.21 | 2.0±0.30 | 22.02±2.05 | 10.25±0.95 | −1.5±0.16 |
| Cystatin C | ||||||
| eGFRcys(AS), current | 4.52±0.42 | 14.23±1.32 | −0.1±0.45 | 28.57±2.14 | 13.30±1.00 | 1.6±0.57 |
| Creatinine–cystatin C | ||||||
| eGFRcr-cys(ASR), current | 4.33±0.37 | 13.63±1.15 | −0.7±0.25 | 25.55±2.05 | 11.89±0.95 | 0.2±0.31 |
| eGFRcr-cys(ASR-NB), new | 4.68±0.37 | 14.72±1.18 | 0.4±0.28 | 25.55±2.04 | 11.89±0.95 | 0.2±0.31 |
| eGFRcr-cys(AS), new | 4.42±0.38 | 13.92±1.19 | −0.4±0.28 | 23.72±2.09 | 11.04±0.97 | −0.7±0.32 |
| eGFR <60 ml/min/1.73 m 2 | ||||||
| Creatinine | ||||||
| eGFRcr(ASR), current | 2.08±0.18 | 6.54±0.56 | Reference | 14.75±0.89 | 6.86±0.41 | Reference |
| eGFRcr(ASR-NB), new | 3.32±0.24 | 10.43±0.76 | 3.9±0.46 | 14.75±0.89 | 6.86±0.41 | 0 |
| eGFRcr(AS), new | 2.72±0.18 | 8.55±0.56 | 2.0±0.26 | 11.34±0.78 | 5.28±0.36 | −1.6±0.16 |
| Cystatin C | ||||||
| eGFRcys(AS), current | 2.17±0.27 | 6.84±0.84 | 0.3±0.66 | 19.04±1.49 | 8.86±0.69 | 2.0±0.62 |
| Creatinine–cystatin C | ||||||
| eGFRcr-cys(ASR), current | 1.90±0.20 | 5.97±0.63 | −0.6±0.39 | 15.49±1.02 | 7.21±0.47 | 0.3±0.35 |
| eGFRcr-cys(ASR-NB), new | 2.30±0.21 | 7.24±0.65 | 0.7±0.37 | 15.49±1.02 | 7.21±0.47 | 0.3±0.35 |
| eGFRcr-cys(AS), new | 1.99±0.20 | 6.28±0.63 | −0.3±0.41 | 13.39±0.98 | 6.23±0.46 | −0.6±0.35 |
| eGFR <45 ml/min/1.73 m 2 | ||||||
| Creatinine | ||||||
| eGFRcr(ASR), current | 0.89±0.14 | 2.80±0.44 | Reference | 4.90±0.46 | 2.28±0.21 | Reference |
| eGFRcr(ASR-NB), new | 1.35±0.13 | 4.23±0.41 | 1.4±0.27 | 4.90±0.46 | 2.28±0.21 | 0 |
| eGFRcr(AS), new | 1.03±0.14 | 3.23±0.44 | 0.4±0.12 | 3.97±0.40 | 1.85±0.19 | −0.4±0.07 |
| Cystatin C | ||||||
| eGFRcys(AS), current | 1.05±0.13 | 3.32±0.41 | 0.5±0.23 | 8.09±0.75 | 3.76±0.35 | 1.5±0.24 |
| Creatinine–cystatin C | ||||||
| eGFRcr-cys(ASR), current | 0.91±0.12 | 2.85±0.37 | 0.1±0.18 | 5.61±0.50 | 2.61±0.23 | 0.3±0.09 |
| eGFRcr-cys(ASR-NB), new | 1.12±0.14 | 3.51±0.43 | 0.7±0.15 | 5.61±0.50 | 2.61±0.23 | 0.3±0.09 |
| eGFRcr-cys(AS), new | 0.99±0.12 | 3.12±0.36 | 0.3±0.21 | 5.01±0.48 | 2.33±0.22 | 0.1±0.10 |
| eGFR <30 ml/min/1.73 m 2 | ||||||
| Creatinine | ||||||
| eGFRcr(ASR), current | 0.45±0.08 | 1.40±0.25 | Reference | 1.10±0.22 | 0.51±0.10 | Reference |
| eGFRcr(ASR-NB), new | 0.57±0.09 | 1.79±0.29 | 0.4±0.12 | 1.10±0.22 | 0.51±0.10 | 0 |
| eGFRcr(AS), new | 0.49±0.09 | 1.54±0.27 | 0.1±0.07 | 0.81±0.16 | 0.38±0.08 | −0.1±0.04 |
| Cystatin C | ||||||
| eGFRcys(AS), current | 0.57±0.09 | 1.81±0.29 | 0.4±0.14 | 2.56±0.40 | 1.19±0.19 | 0.7±0.11 |
| Creatinine–cystatin C | ||||||
| eGFRcr-cys(ASR), current | 0.55±0.09 | 1.72±0.27 | 0.3±0.12 | 1.85±0.35 | 0.86±0.16 | 0.4±0.08 |
| eGFRcr-cys(ASR-NB), new | 0.57±0.09 | 1.80±0.28 | 0.4±0.13 | 1.85±0.35 | 0.86±0.16 | 0.4±0.08 |
| eGFRcr-cys(AS), new | 0.55±0.09 | 1.72±0.27 | 0.3±0.12 | 1.71±0.29 | 0.80±0.13 | 0.3±0.07 |
Plus–minus values are means ±SE.
The equations are referred to by the filtration marker or markers (creatinine [eGFRcr], eGFRcys [cystatin C], or creatinine–cystatin C [eGFRcr-cys]) and the demographic factors (age, sex, and race [ASR] or age and sex [AS]) that were used in their development. Non-Black (NB) refers to equations in which the Black race coefficient was removed.
Change was calculated as the difference in weighted percent from eGFRcr(ASR).
Chronic kidney disease was defined as a GFR of less than 60 ml per minute per 1.73 m2 or persistent albuminuria (urinary albumin-to-creatinine ratio [with albumin measured in milligrams and creatinine measured in grams] of >30).